Dr Victoria Homer (Co-Director), University of Birmingham
Professor Pamela Kearns, University of Birmingham
Professor Timothy Barrett, University of Birmingham
Professor Simon Gates, University of Birmingham
Professor Steven Julious, University of Sheffield
Professor Carrol Gamble, University of Liverpool
The CAPTIVATE node will bring together the UK’s leading trial experts with hospital researchers experienced in rare diseases, industry partners, regulators, policy makers and patient partners, to develop better ways to test new medicines for people with rare diseases in clinical trials. People expect to receive treatments which have been approved for use in the NHS based on evidence from trials but it is hard to do trials in rare diseases because there may only be a few people affected with the disease who are able to take part. Often a clinical trial will require several phases, one after the other, but this is not feasible in rare diseases so we will develop ways to test medicines in a single trial (a ‘one-stop-study’) that collects all the evidence needed to approve the treatment in one go. We will explore how best to include the information about a medicine that is already known to ensure trial results are more likely to be accepted by healthcare professionals, people living with rare diseases and the authorities who set the rules for approving new medicines. One type of trial that is often used, called a “randomised controlled trial”, has participants assigned to two or more groups, where one of the groups receive whatever treatment would be considered as standard of care for that disease. This group is called the “control arm”.
We will look for alternatives to including a control arm in studies to reduce the number of participants needed. We will investigate alternative approaches to statistical analysis of the data from trials, such as those based on the Bayesian method, named after a scientist called Thomas Bayes, that may be useful in trials of rare diseases because they can be more flexible and may help to reduce the number of patients needed to take part.
We will work on trials in children, where it is so important to make sure medicines that work get to children with rare diseases quickly and explore how we can best test medicines in ultra-rare diseases.
© 2023 Copyright Rare Disease Research UK
